2992 related articles for article (PubMed ID: 16840928)
1. [Cognition, schizophrenia and the effect of antipsychotics].
Stip E
Encephale; 2006; 32(3 Pt 1):341-50. PubMed ID: 16840928
[TBL] [Abstract][Full Text] [Related]
2. [Hypofrontality and negative symptoms in schizophrenia: synthesis of anatomic and neuropsychological knowledge and ecological perspectives].
Semkovska M; Bédard MA; Stip E
Encephale; 2001; 27(5):405-15. PubMed ID: 11760690
[TBL] [Abstract][Full Text] [Related]
3. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
4. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
Houthoofd SA; Morrens M; Sabbe BG
Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
[TBL] [Abstract][Full Text] [Related]
5. Schizophrenic patients treated with clozapine or olanzapine perform better on theory of mind tasks than those treated with risperidone or typical antipsychotic medications.
Savina I; Beninger RJ
Schizophr Res; 2007 Aug; 94(1-3):128-38. PubMed ID: 17560766
[TBL] [Abstract][Full Text] [Related]
6. Comparison between olanzapine and haloperidol on procedural learning and the relationship with striatal D2 receptor occupancy in schizophrenia.
Paquet F; Soucy JP; Stip E; Lévesque M; Elie A; Bédard MA
J Neuropsychiatry Clin Neurosci; 2004; 16(1):47-56. PubMed ID: 14990759
[TBL] [Abstract][Full Text] [Related]
7. Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.
Bernardo M; Parellada E; Lomeña F; Catafau AM; Font M; Gómez JC; López-Carrero C; Gutiérrez F; Pavía J; Salamero M
Psychiatry Res; 2001 Aug; 107(2):87-97. PubMed ID: 11530275
[TBL] [Abstract][Full Text] [Related]
8. Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison.
Crespo-Facorro B; Rodríguez-Sánchez JM; Pérez-Iglesias R; Mata I; Ayesa R; Ramirez-Bonilla M; Martínez-Garcia O; Vázquez-Barquero JL
J Clin Psychiatry; 2009 Apr; 70(5):717-29. PubMed ID: 19389335
[TBL] [Abstract][Full Text] [Related]
9. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia.
Meltzer HY; McGurk SR
Schizophr Bull; 1999; 25(2):233-55. PubMed ID: 10416729
[TBL] [Abstract][Full Text] [Related]
10. The effect of neuroleptic treatments on executive function and symptomatology in schizophrenia: a 1-year follow up study.
Rémillard S; Pourcher E; Cohen H
Schizophr Res; 2005 Dec; 80(1):99-106. PubMed ID: 16162401
[TBL] [Abstract][Full Text] [Related]
11. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol.
Markianos M; Hatzimanolis J; Lykouras L
Eur Arch Psychiatry Clin Neurosci; 2001 Jun; 251(3):141-6. PubMed ID: 11697576
[TBL] [Abstract][Full Text] [Related]
14. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
[TBL] [Abstract][Full Text] [Related]
15. Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol.
Purdon SE; Woodward N; Lindborg SR; Stip E
Psychopharmacology (Berl); 2003 Sep; 169(3-4):390-7. PubMed ID: 12827347
[TBL] [Abstract][Full Text] [Related]
16. Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.
Nørbak-Emig H; Ebdrup BH; Fagerlund B; Svarer C; Rasmussen H; Friberg L; Allerup PN; Rostrup E; Pinborg LH; Glenthøj BY
Int J Neuropsychopharmacol; 2016 May; 19(5):. PubMed ID: 26819282
[TBL] [Abstract][Full Text] [Related]
17. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
Kapur S; Zipursky RB; Remington G
Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
[TBL] [Abstract][Full Text] [Related]
18. Novel pharmacological approaches to the treatment of schizophrenia.
Fink-Jensen A
Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
[TBL] [Abstract][Full Text] [Related]
19. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
Dresel S; Tatsch K; Dähne I; Mager T; Scherer J; Hahn K
J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
[TBL] [Abstract][Full Text] [Related]
20. Insight in persons with schizophrenia: effects of switching from conventional neuroleptics to atypical antipsychotics.
Aguglia E; De Vanna M; Onor ML; Ferrara D
Prog Neuropsychopharmacol Biol Psychiatry; 2002 Dec; 26(7-8):1229-33. PubMed ID: 12502008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]